SCHEMBL12188014

SCHEMBL12188014

COc1ccccc1Cn1nc2c(N)nc3ccccc3n2c1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 9/20 0.55
▸ ADORA2A P29274 9/20 0.55
▸ ADORA1 P30542 5/20 0.55
▸ LMNA P02545 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ AKT1 P31749 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188029 0.89 ADORA3 (0.55) ADORA3ADORA2AADORA1
SCHEMBL12165580 0.87 ADORA3 (0.49) ADORA3ADORA2AADORA1LMNAHTT
SCHEMBL16065954 0.86 ADORA3 (0.55) ADORA3ADORA2AADORA1KDM4EMEN1
SCHEMBL12165529 0.85 ADORA3 (0.56) ADORA3ADORA2AADORA1LMNAHTT
SCHEMBL12165502 0.85 ADORA3 (0.56) ADORA3ADORA2AADORA1
SCHEMBL12165723 0.83 ADORA3 (0.49) ADORA3ADORA2AADORA1LMNATSHR
SCHEMBL12165501 0.83 ADORA3 (0.54) ADORA3ADORA2AADORA1
SCHEMBL16065952 0.83 ADORA3 (0.56) ADORA3ADORA2AADORA1LMNATSHR
SCHEMBL12165745 0.81 ADORA3 (0.50) ADORA3ADORA2AADORA1KDM4EMEN1
SCHEMBL14922472 0.81 ADORA3 (0.50) ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435994-B2 Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 — — US disclosed
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback